SUPPLEMENTARY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Total revenues	$ 18,754	$ 16,868	$ 14,256	$ 14,503	$ 17,565	$ 15,693	$ 13,749	$ 10,417	$ 64,381	$ 57,424
Total expenses	27,954	27,705	29,961	25,710	23,805	24,453	29,872	35,329	111,330	113,459
Loss from operations	(9,200)	(10,837)	(15,705)	(11,207)	(6,240)	(8,760)	(16,123)	(24,912)	(46,949)	(56,035)
Net loss	$ (15,527)	$ (12,698)	$ (16,529)	$ (11,664)	$ (8,510)	$ (8,950)	$ (15,645)	$ (22,088)	$ (56,418)	$ (55,193)
Net loss per share - basic (in dollars per share)	$ (0.31)	$ (0.26)	$ (0.34)	$ (0.24)	$ (0.17)	$ (0.17)	$ (0.28)	$ (0.35)	$ (1.15)	$ (1)
Net loss per share - diluted (in dollars per share)	$ (0.31)	$ (0.26)	$ (0.34)	$ (0.24)	$ (0.17)	$ (0.17)	$ (0.28)	$ (0.35)	$ (1.15)	$ (1)
Percentage of profit share									35.00%
YUPELRI Monotherapy
Total revenues	$ 23,339	$ 21,766	$ 19,085	$ 19,329	$ 21,225	$ 20,414	$ 19,263	$ 16,434
Percentage of net sales									35.00%
Mylan
Percentage of profit share									65.00%